最終更新日: 2026年8月28日
Kidney cancer is usually silent, and most kidney masses today are found by accident — on a scan done for something else, or as part of a health-check package. A small renal mass means a solid kidney lesion under four centimetres, and it presents a genuine dilemma: it might be cancer, and it might not.
Broadly, around eight in ten turn out to be malignant and two in ten benign — with the benign proportion higher the smaller the lesion. Removing all of them means operating on a substantial number of people who never needed it, which is the problem biopsy was introduced to solve.
- タイ・バンコク病院 泌尿器科センター オンライン予約 02-310-3009 bhquro@bdms.co.th
- サミティベート・シラチャ病院(チョンブリ) 088-022-1445
The question is not whether biopsy is possible
It is whether the result would change anything. That principle was implied in the earlier version of this article and is worth stating outright, because it decides who should have one.
Where a biopsy earns its place
- Before ablation — freezing or heating the tumour destroys it without producing a specimen, so the diagnosis has to be made beforehand.
- Where surgery would be a serious undertaking — an older patient, significant heart or lung disease, one kidney, or poor kidney function. Knowing whether the lesion is benign changes whether the risk is worth taking.
- Where surveillance is being considered rather than treatment, and the patient wants to know what is being watched.
- Where the mass might not be a primary kidney cancer at all — lymphoma, or a deposit from a cancer elsewhere, both of which are treated by an oncologist rather than a surgeon.
Where it can reasonably be skipped — absent from the earlier version
- A fit patient with a clearly suspicious mass who is proceeding to surgery anyway. The operation provides the diagnosis, and a biopsy adds a procedure without changing the plan.
- A mass containing visible fat on CT, which is characteristic enough of a benign angiomyolipoma that a needle is not needed.
- Predominantly cystic lesions, which biopsy samples poorly and which are assessed and followed on imaging instead.

What the procedure involves
You lie face down, local anaesthetic is injected over the flank, and two or three tissue cores are taken with a fine needle guided by ultrasound or CT. It is an outpatient procedure, usually with a period of observation afterwards.
Access is harder where there is a lot of body fat between skin and kidney, and posterior masses are easier to reach than those at the front. Blood-thinning medication has to be discussed and usually paused beforehand — this is a needle into a highly vascular organ, and that discussion was missing from the earlier version. Do not stop such medication on your own; the timing is arranged with the prescriber.
The limitation that matters most
The earlier version quoted an accuracy of up to 92% and a complication rate under 2%. Both figures are fair. What was missing is the number patients actually need.
Roughly one biopsy in ten comes back non-diagnostic — not benign, not malignant, simply not enough usable tissue to say. The 92% figure describes how accurate the answer is when there is an answer; it is not the chance of getting one. A non-diagnostic result usually leads to a repeat biopsy, and the second attempt is often successful.
And the consequence that follows: a non-diagnostic biopsy does not mean the mass is benign. A suspicious lesion with an inconclusive biopsy is still a suspicious lesion, and is managed as one.
Risks
- Bleeding around the kidney — the commonest, usually minor and self-limiting, occasionally requiring transfusion or a procedure to stop it.
- Blood in the urine and flank pain, generally settling within days.
- Air in the chest cavity, uncommon, and relevant for upper-pole masses close to the lung.
- Tumour spreading along the needle track — a long-standing worry that modern technique has reduced to something close to negligible. It is worth mentioning precisely because patients ask, and the honest answer reassures.
What happens with the result
If it shows cancer
The options are surgery — removing the tumour and sparing the rest of the kidney where possible — ablation、または active surveillance. That last one deserves more than a mention in a list, because it is frequently the right answer and patients rarely expect it: many small kidney cancers grow very slowly, and in an older person with other conditions, watching a small tumour on scans is often safer than operating on it. The biopsy result and the grade help decide which.
If it shows a benign mass — a correction
The earlier version said that a benign result leads to surveillance, with repeat biopsy considered if the mass exceeds 4 cm or grows faster than 5 mm a year. Those thresholds are the triggers for reconsidering treatment during surveillance, not for repeating a biopsy, and the statement has been rewritten.
What actually follows depends on which benign diagnosis it is — they behave differently and are followed differently. And the point behind the confusion is worth keeping: a benign biopsy is reassuring rather than final. A needle samples part of a lesion, so a mass that continues to enlarge is reassessed regardless of what the first biopsy said. Surveillance is not discharge.

当日中の受診が必要な症状
タイで緊急の場合は、次の番号に電話してください 1669.
- After a biopsy: severe or worsening flank pain, heavy bleeding or clots in the urine, dizziness, breathlessness or a racing pulse, or fever.
- 尿中に血が見える that has not been investigated — see 血尿.
- A mass you can feel in the abdomen or flank, or persistent flank pain with weight loss or fevers.
- New swelling of the legs, or a varicocele appearing on the right side をご覧ください。 精索静脈瘤, where this is explained as a reason to image the abdomen.
- A scan report mentioning a kidney lesion that was never followed up. Not urgent today, and the item most likely to matter.
Frequently Asked Questions About Kidney Mass Biopsy
私の腎臓の腫瘍には生検が必要ですか?
Only if the result would change what happens next. It is valuable before ablation, where surgery carries significant risk, where surveillance is being considered, or where the mass might not be a primary kidney cancer. A fit patient proceeding to surgery anyway, a mass containing fat on CT, and predominantly cystic lesions can reasonably skip it.
How accurate is it?
Highly accurate when it yields an answer — up to around 92%. What matters alongside that is that roughly one biopsy in ten is non-diagnostic, meaning not enough usable tissue to say either way. That usually leads to a repeat, and a non-diagnostic result does not mean the mass is benign.
Is it safe? Could the needle spread the cancer?
Complications occur in under 2% and are mostly bleeding around the kidney, blood in the urine and flank pain, almost always settling on their own. Spread along the needle track was a genuine historical concern and modern technique has reduced it to something close to negligible. Blood-thinning medication is reviewed beforehand.
The biopsy showed a benign mass. Am I discharged?
No. A needle samples part of a lesion, so a benign result is reassuring rather than final, and follow-up imaging continues. What that follow-up looks like depends on which benign diagnosis it is. A mass that keeps growing is reassessed regardless of the first result.
If it is cancer, does it have to be removed?
Not necessarily. Many small kidney cancers grow very slowly, and in an older person with other medical conditions, monitoring a small tumour on scans is often safer than operating. Surgery, ablation and active surveillance are all legitimate options, and the biopsy result helps decide between them.
診察のご予約について
Dr. Soarawee Weerasopone の診察場所は次のとおりです Bangkok Hospital Headquarters また、チョンブリー県の Samitivej Sriracha Hospital でも次の曜日に診察を行っています 088-022-1445. Bring the scan images themselves rather than only the report, together with any earlier scans — whether the lesion has changed since a previous scan is often the most useful single piece of information — and a list of your medicines including any blood thinner.
来院が難しい海外の患者さんを含め、バンコク病院の遠隔診療をご利用いただけます。事前に泌尿器科へ次のメールアドレスまでご連絡のうえ、ご予約ください: bhquro@bdms.co.th。サミティベート・シラチャー病院は対面診療のみです。費用に関するお問い合わせには病院が対応しており、本ウェブサイトでは対応しておりません。
免責事項: 本コンテンツは、Bangkok Hospital Headquarters に勤務する泌尿器科専門医(認定医)の Dr. Soarawee Weerasopone が執筆・監修したもので、教育目的のみを意図しています。個々の方に対する医学的助言、診断、処方ではなく、個人メッセージやソーシャルメディアを通じて助言、診断、処方を行うことはありません。Dr. Soarawee は公開のソーシャルメディアアカウントを運営しておらず、彼の名前で個別相談を提供するアカウントは詐欺です。タイで緊急の場合は、次の番号に電話してください 1669.
医学的な執筆・監修:ソアラウィー・ウェーラソポーン医師(ドクター・ポム)― 泌尿器科専門医、バンコク病院本院、2016年より泌尿器科臨床に従事。専門研修:ロボット支援手術、長庚紀念医院、台湾(2019年) · 見学研修:内泌尿器科、順天堂大学医学部附属順天堂医院、東京(2022年) · 研究員および臨床見学者、スコット泌尿器科部門、ベイラー医科大学、米国(2025~2026年)。.

ソアラウィー・ウィーラソーポン医師(ポム医師)は、Bangkok Hospital Headquarters の泌尿器科専門医(ボード認定)で、男性医療、ロボット手術(da Vinci Xi)、腎結石治療を専門としています。台湾の Chang Gung Memorial Hospital にてアンドロロジー(男性科)およびロボット手術・低侵襲泌尿器科の2つの臨床フェローシップ(2019年)、東京の Juntendo University Hospital にてエンドウロロジー・オブザーバーシップ(2022年)、ベイラー医科大学スコット泌尿器科にてモヒト・ケラ教授のもとリサーチスカラー兼クリニカルオブザーバー(2025〜2026年)を修了しています。

